Literature DB >> 7776833

Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells.

G A Cabral1, D M Toney, K Fischer-Stenger, M P Harrison, F Marciano-Cabral.   

Abstract

Anandamide (arachidonoylethanolamide) was shown to inhibit macrophage-mediated killing of tumor necrosis factor-sensitive murine L929 fibroblasts. Scanning electron microscopy (SEM) demonstrated that L929 cells, co-cultured with Propionibacterium acnes (P. acnes)-activated peritoneal macrophages from mice treated with vehicle, were either disrupted or had surface abnormalities and numerous punctate lesions. In contrast, L929 cells co-cultured with macrophages from mice receiving P. acnes in concert with Anandamide (20 mg/kg-80 mg/kg) or the exogenous cannabinoid delta-9-tetrahydrocannabinol (THC; 80 mg/kg) did not exhibit ultrastructural abnormalities. Cytotoxicity assays were performed in parallel with SEM in order to determine whether ultrastructural observations correlated with target cell killing as measured by release of radiolabel from L929 target cells. P. acnes-activated macrophages from vehicle-treated mice elicited 41% specific release of radiolabel from [51Cr]-labeled L929 cells. In contrast, macrophages from animals treated with P. acnes and with 20, 40, or 80 mg/kg Anandamide exhibited 38%, 25%, or 28% specific release of radiolabel, respectively. Similarly, macrophages from animals treated with P. acnes and with 80 mg/kg THC exhibited 21% specific release of radiolabel. In vitro cytotoxicity studies using radiolabeled L929 target cells and conditioned medium from RAW264.7 murine macrophage-like cells allowed for determination of the time interval over which Anandamide exerted its inhibitory effect. Maximal inhibition of target cell killing occurred when conditioned medium was obtained from macrophages exposed to Anandamide for 1 hr prior to activation. In contrast, conditioned medium from THC-treated macrophages exerted its maximal inhibition of target cell killing when obtained from RAW264.7 cells pretreated for 24hr-48hr prior to activation. These results indicate that Anandamide and THC exert a similar inhibition of killing of TNF-sensitive target cells. However, the time interval over which these two substances elicit their suppressive effect differs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7776833     DOI: 10.1016/0024-3205(95)00190-h

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  18 in total

1.  Alcohol Versus Cannabinoids: A Review of Their Opposite Neuro-Immunomodulatory Effects and Future Therapeutic Potentials.

Authors:  Madhavan P Nair; Gloria Figueroa; Gianna Casteleiro; Karla Muñoz; Marisela Agudelo
Journal:  J Alcohol Drug Depend       Date:  2015-01-23

Review 2.  [The endogenous cannabinoid system. Therapeutic implications for neurologic and psychiatric disorders].

Authors:  U Schneider; J Seifert; M Karst; J Schlimme; K Cimander; K R Müller-Vahl
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

Review 3.  Endocannabinoids and immune regulation.

Authors:  Rupal Pandey; Khalida Mousawy; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Pharmacol Res       Date:  2009-04-07       Impact factor: 7.658

Review 4.  Endocannabinoid signalling in innate and adaptive immunity.

Authors:  Valerio Chiurchiù; Luca Battistini; Mauro Maccarrone
Journal:  Immunology       Date:  2015-03       Impact factor: 7.397

5.  A biosynthetic pathway for anandamide.

Authors:  Jie Liu; Lei Wang; Judith Harvey-White; Douglas Osei-Hyiaman; Raj Razdan; Qian Gong; Andrew C Chan; Zhifeng Zhou; Bill X Huang; Hee-Yong Kim; George Kunos
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-28       Impact factor: 11.205

Review 6.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

7.  The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.

Authors:  L De Petrocellis; D Melck; A Palmisano; T Bisogno; C Laezza; M Bifulco; V Di Marzo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

8.  The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor.

Authors:  Erinn S Raborn; Francine Marciano-Cabral; Nancy E Buckley; Billy R Martin; Guy A Cabral
Journal:  J Neuroimmune Pharmacol       Date:  2007-07-11       Impact factor: 4.147

9.  Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates.

Authors:  W Gonsiorek; C A Lunn; X Fan; G Deno; J Kozlowski; R W Hipkin
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

Review 10.  Downstream effects of endocannabinoid on blood cells: implications for health and disease.

Authors:  Valeria Gasperi; Daniela Evangelista; Isabella Savini; Domenico Del Principe; Luciana Avigliano; Mauro Maccarrone; Maria Valeria Catani
Journal:  Cell Mol Life Sci       Date:  2015-05-10       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.